Since the discovery of KRAS gene mutations in 1983, researchers have worked to develop new therapies that target this protein when treating cancer. Unfortunately, KRAS mutations have long been considered impossible to treat with drugs, but MD Anderson researchers have made recent breakthroughs in developing targeted therapies with promising results.
Shubham Pant, M.D., associate professor of Investigational Cancer Therapeutics...
B-cell lymphoma isn’t one disease. There are about 63 subtypes, with diffuse large B-cell lymphoma (DLBCL) being the most common. A chemotherapy...
First emerging almost three decades ago, monoclonal antibodies are changing the way doctors treat cancer and other illnesses, including COVID...
In the last decade, immunotherapy has become a viable treatment option for many cancer patients. Unlike radiation and chemotherapy, immunotherapy does not target the cancer itself. Instead, it enables a patient’s own immune system to attack the disease. In most cases, immune-based treatments stimulate T cells, a specialized type of immune cell, to fight cancer.
Immunotherapy drugs called immune checkpoint inhibitors accomplish...
After completing a course of treatment, there are few words that sound better to a patient than “complete remission.” It’s an indication that...
Natural killer cells – or NK cells – are part of our immune system. They patrol our bodies for abnormal cells like cancer and destroy them...
Lori Shults didn’t know much about clinical trials when she first came to MD Anderson in May 2017. “I thought they involved some people getting...
MD Anderson’s Moon Shots Program™ increases the speed at which our experts turn their research into new cancer treatment options for patients...
Courage. Hope. Love. Faith. Strength. Wisdom. These are a few of the gifts that our cancer survivors shared with us on Cancerwise this past...
A cancer diagnosis can provoke a range of emotions and prompt endless questions. So throughout the year, we shared dozens of insights from...